특이적 결합 분자
본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다. The present invention relates to specific binding molecul...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Patent |
Sprache: | kor |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | DIAS DO NASCIMENTO JORGE JAMES PETER O'DWYER RONAN HAYES CONOR CHILLAKURI CHANDRAMOULI PARKER JAMES POOLE ANDREW |
description | 본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다.
The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20220087511A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20220087511A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20220087511A3</originalsourceid><addsrcrecordid>eNrjZBB_27XzzdwtbxY0KrzatOHt1JUKr7e1vJk3gYeBNS0xpziVF0pzMyi7uYY4e-imFuTHpxYXJCan5qWWxHsHGRkYGRkYWJibGho6GhOnCgD9mylC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>특이적 결합 분자</title><source>esp@cenet</source><creator>DIAS DO NASCIMENTO JORGE ; JAMES PETER ; O'DWYER RONAN ; HAYES CONOR ; CHILLAKURI CHANDRAMOULI ; PARKER JAMES ; POOLE ANDREW</creator><creatorcontrib>DIAS DO NASCIMENTO JORGE ; JAMES PETER ; O'DWYER RONAN ; HAYES CONOR ; CHILLAKURI CHANDRAMOULI ; PARKER JAMES ; POOLE ANDREW</creatorcontrib><description>본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다.
The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.</description><language>kor</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220624&DB=EPODOC&CC=KR&NR=20220087511A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220624&DB=EPODOC&CC=KR&NR=20220087511A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>DIAS DO NASCIMENTO JORGE</creatorcontrib><creatorcontrib>JAMES PETER</creatorcontrib><creatorcontrib>O'DWYER RONAN</creatorcontrib><creatorcontrib>HAYES CONOR</creatorcontrib><creatorcontrib>CHILLAKURI CHANDRAMOULI</creatorcontrib><creatorcontrib>PARKER JAMES</creatorcontrib><creatorcontrib>POOLE ANDREW</creatorcontrib><title>특이적 결합 분자</title><description>본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다.
The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBB_27XzzdwtbxY0KrzatOHt1JUKr7e1vJk3gYeBNS0xpziVF0pzMyi7uYY4e-imFuTHpxYXJCan5qWWxHsHGRkYGRkYWJibGho6GhOnCgD9mylC</recordid><startdate>20220624</startdate><enddate>20220624</enddate><creator>DIAS DO NASCIMENTO JORGE</creator><creator>JAMES PETER</creator><creator>O'DWYER RONAN</creator><creator>HAYES CONOR</creator><creator>CHILLAKURI CHANDRAMOULI</creator><creator>PARKER JAMES</creator><creator>POOLE ANDREW</creator><scope>EVB</scope></search><sort><creationdate>20220624</creationdate><title>특이적 결합 분자</title><author>DIAS DO NASCIMENTO JORGE ; JAMES PETER ; O'DWYER RONAN ; HAYES CONOR ; CHILLAKURI CHANDRAMOULI ; PARKER JAMES ; POOLE ANDREW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20220087511A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>kor</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>DIAS DO NASCIMENTO JORGE</creatorcontrib><creatorcontrib>JAMES PETER</creatorcontrib><creatorcontrib>O'DWYER RONAN</creatorcontrib><creatorcontrib>HAYES CONOR</creatorcontrib><creatorcontrib>CHILLAKURI CHANDRAMOULI</creatorcontrib><creatorcontrib>PARKER JAMES</creatorcontrib><creatorcontrib>POOLE ANDREW</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>DIAS DO NASCIMENTO JORGE</au><au>JAMES PETER</au><au>O'DWYER RONAN</au><au>HAYES CONOR</au><au>CHILLAKURI CHANDRAMOULI</au><au>PARKER JAMES</au><au>POOLE ANDREW</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>특이적 결합 분자</title><date>2022-06-24</date><risdate>2022</risdate><abstract>본 발명은 생식세포 암 항원 MAGEA1로부터 유래된 HLA-A*02 제한 펩타이드 KVLEYVIKV (서열 번호: 1)에 결합하는 T 세포 수용체 (TCR)와 같은 특이적 결합 분자에 관한 것이다. 특이적 결합 분자는 고유 MAGEA1 TCR에 비해 알파 및/또는 베타 가변 도메인 내의 비-천연 돌연변이를 포함할 수 있다. 본 발명의 특이적 결합 분자는 악성 질환의 치료를 위한 신규 면역치료 시약으로서 사용하기에 특히 적합하다.
The present invention relates to specific binding molecules, such as T cell receptors (TCRs), that bind the HLA-A*02 restricted peptide KVLEYVIKV (SEQ ID NO: 1) derived from the germline cancer antigen MAGEA1. The specific binding molecules may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGEA1 TCR. The specific binding molecules of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | kor |
recordid | cdi_epo_espacenet_KR20220087511A |
source | esp@cenet |
subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | 특이적 결합 분자 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T12%3A07%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=DIAS%20DO%20NASCIMENTO%20JORGE&rft.date=2022-06-24&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20220087511A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |